Compare Cronos Group Inc (CRON) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Oklo Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Oklo Inc trades at $35.21 (market cap $6.43B). The key difference: Oklo Inc is far larger — about 5.4× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Oklo Inc for 31 Days on average.
| CRON | OKLO | |
|---|---|---|
Market Cap | $1.18B | $6.43B |
Volume | 968,037 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $3.55 | $174.14 |
52-Week Low | $2.30 | $34.57 |
Typical Hold Time | 22 Days | 31 Days |
Enterprise Value | $387.62M | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
OKLO trades at $36.82, down 4.49% on the day, with bearish technical indicators showing resistance at $37-38. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strongly bullish with a $78.63 price target. Recent news highlights nuclear energy sector momentum but notes OKLO's early commercialization stage and recent $1 billion stock sale.
Outlook hinges on project pipeline execution amid substantial cash burn. High institutional support via financing ($1.26B in 2025) fuels growth bets, but profitability remains distant with a -12,625.54% net margin. Risks include dilution from equity raises and intense SMR competition. The stock offers speculative upside if contracts materialize but carries high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
